Administration of HRI Activators as a Promising Treatment Strategy for T2DM and Non-Alcoholic Fatty Liver Disease¹

Fibroblast growth factor 21 (FGF21) has emerged as a treatment for type 2 diabetes mellitus (T2DM), however with the limitation to be administered only via a subcutaneous injection, the effects of haem-regulated eukaryotic translation initiation factor 2α kinase (HRI) activator was examined. It has been previously demonstrated that HRI activators increases the hepatic and circulating effects of FGF21. Therefore, the oral administration of a new HRI activator, EPB-53, showed a reduction in body weight gain, improved glucose intolerance and prevented hepatic steatosis and hypertriglyceridaemia in mice on a high-fat diet. The findings of this study indicated the promising treatment strategy of T2DM and non-alcoholic fatty liver disease.

Refence

1. Zarei M, et al. Brit J Pharm 2019;176:2292-2305.